DSM-Firmenich elects Ridinger. DSM-Firmenich stock sits above target

Published on 10/26/2026 at 15:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock trades at EUR 108.28 on October 26, 2026. It is 12.24 percent above the EUR 96.47 average target before November 3 sales.

DSM-Firmenich stock faces a valuation test

DSM-Firmenich elected Richard Ridinger as board chairman on October 19, 2026.
The stock was 12.24 percent above the EUR 96.47 average analyst target listed by MarketScreener.
At Lang & Schwarz, the stock was trading at EUR 108.28 on October 26, 2026 at 3:40 p.m. CEST.

DSM-Firmenich, CH1216478797, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 108.28 at Lang & Schwarz on October 26, 2026 at 3:40 p.m. CEST. The company elected Richard Ridinger as chairman on October 19, while the latest average analyst target stands at EUR 96.47, putting the stock 12.24 percent above that level.

The leadership change is documented in dsm-firmenich's October 19, 2026 release. Shareholders at the Extraordinary General Meeting elected Ridinger to succeed Thomas Leysen, who retired from the board.

Board change meets a demanding valuation

Ridinger has served as an independent director since 2023 and also joined the Compensation Committee, according to the company release. His background spans Pharma, Home and Personal Care, and Nutrition and Health, linking the appointment to the group's operating areas.

The market question is now whether the new chair can support execution while expectations remain elevated. MarketScreener listed an average target of EUR 96.47 and a mean consensus of Outperform as of October 23, 2026. The target is 10.90 percent below the EUR 108.90 closing price shown on that page.

November 3 brings the next test

The next scheduled company event is the third-quarter sales release on November 3, 2026, listed in the same MarketScreener company calendar. That update will give investors a fresh operating reference after first-half continuing-operations revenue exceeded EUR 4.6 billion, a figure also described in the company background materials.

The contrast is clear: governance has moved forward, but the share price is above the prevailing average target. The November sales release therefore carries more weight for judging whether the valuation gap is supported by operating momentum.

DSM-Firmenich stock stays above target

DSM-Firmenich was trading at EUR 108.28 at Lang & Schwarz on October 26, 2026 at 3:40 p.m. CEST. The stock was 12.24 percent above the EUR 96.47 average analyst target, while the next scheduled sales release is November 3, 2026. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.